Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma

Summary

This study will determine the response rate of daily low dose interferon-alpha-2b in patients with metastatic or unresectable clear cell renal cell carcinoma.

Timeline

Start

—

Primary completion

—

Completion

2006-11

Outcome

Outcome not reported

Stopped: “Withdrawn in October 2006, no longer of interest”

Drugs

Indications